Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?

CRISPR Therapeutics' (NASDAQ: CRSP) stock may be down by 21% this year so far, but that doesn't mean you should write it off as a potential investment. The innovative developer of gene therapies is making headway. And its pipeline implies a cornucopia of opportunities for the stock to rise over the coming years, especially if its cardiovascular medicine and oncology programs pan out.Still, investing in biotech companies isn't for the faint of heart, and even a slightly less risky contender like CRISPR Therapeutics could have a few pitfalls lurking. Let's take a look at where this biotech is going, and whether it could be a good fit for your portfolio this year.In the near term, there's a very clear path for this company to massively increase the size of its top line, and the medium term also offers a high probability of earnings growth. Here's why.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool